BACKGROUND AND OBJECTIVES: There is only limited experience with conditioning regimens based on busulfan for patients with acute lymphoblastic leukemia (ALL). Therefore, the aim of this study was to compare the event-free survival (EFS), transplant-related mortality (TRM) and the probability of relapse (PR) of patients undergoing hematopoietic cell transplantation (HCT) for ALL conditioned with or without total body irradiation (TBI). DESIGN AND METHODS: The study sample consisted of 156 patients conditioned with regimens based on TBI (n=114) or on high doses of oral busulfan (BU) (n=42). Most of the BU group received phenytoin as prophylaxis for seizures. The median follow-up was 6 years. RESULTS: EFS at 6 years was 43% (95% CI 35%-51%) versus 22% (95% CI 10%-34%) in the TBI and BU subsets respectively (p=0.01). TRM at 18 months was 22% and 17% in the BU and TBI groups (p=0.24), respectively. At 3 years actuarial PR was 71% in the BU group and 47% in the TBI group (p=0.01). In the multivariable analysis, a worse EFS was associated with BU, relative risk (RR) 1.7; advanced disease versus 1st and 2nd complete remission (CR) at HCT, RR 2.5; absence of chronic graft-versus-host disease, RR 1.8; development of veno-occlusive disease RR 2.2 and shorter CR duration before transplant. INTERPRETATION AND CONCLUSIONS. TBI was associated with a lower relapse rate and better EFS, even in patients in 1(st )and 2(nd) CR, than schemes based on high doses of busulfan. This suggests that conditioning regimens based on TBI should remain the standard method of preparative regimen for patients with ALL.
BACKGROUND AND OBJECTIVES: There is only limited experience with conditioning regimens based on busulfan for patients with acute lymphoblastic leukemia (ALL). Therefore, the aim of this study was to compare the event-free survival (EFS), transplant-related mortality (TRM) and the probability of relapse (PR) of patients undergoing hematopoietic cell transplantation (HCT) for ALL conditioned with or without total body irradiation (TBI). DESIGN AND METHODS: The study sample consisted of 156 patients conditioned with regimens based on TBI (n=114) or on high doses of oral busulfan (BU) (n=42). Most of the BU group received phenytoin as prophylaxis for seizures. The median follow-up was 6 years. RESULTS: EFS at 6 years was 43% (95% CI 35%-51%) versus 22% (95% CI 10%-34%) in the TBI and BU subsets respectively (p=0.01). TRM at 18 months was 22% and 17% in the BU and TBI groups (p=0.24), respectively. At 3 years actuarial PR was 71% in the BU group and 47% in the TBI group (p=0.01). In the multivariable analysis, a worse EFS was associated with BU, relative risk (RR) 1.7; advanced disease versus 1st and 2nd complete remission (CR) at HCT, RR 2.5; absence of chronic graft-versus-host disease, RR 1.8; development of veno-occlusive disease RR 2.2 and shorter CR duration before transplant. INTERPRETATION AND CONCLUSIONS. TBI was associated with a lower relapse rate and better EFS, even in patients in 1(st )and 2(nd) CR, than schemes based on high doses of busulfan. This suggests that conditioning regimens based on TBI should remain the standard method of preparative regimen for patients with ALL.
Authors: Mitchell Sabloff; Saurabh Chhabra; Tao Wang; Caitrin Fretham; Natasha Kekre; Allistair Abraham; Kehinde Adekola; Jeffery J Auletta; Christopher Barker; Amer M Beitinjaneh; Christopher Bredeson; Jean-Yves Cahn; Miguel Angel Diaz; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Usama Gergis; Eva Guinan; Betty K Hamilton; Shahrukh Hashmi; Peiman Hematti; Gerhard Hildebrandt; Leona Holmberg; Sanghee Hong; Hillard M Lazarus; Rodrigo Martino; Lori Muffly; Taiga Nishihori; Miguel-Angel Perales; Jean Yared; Shin Mineishi; Edward A Stadtmauer; Marcelo C Pasquini; Alison W Loren Journal: Biol Blood Marrow Transplant Date: 2019-08-29 Impact factor: 5.742
Authors: Kathleen M Overholt; Satoru Otsuru; Timothy S Olson; Adam J Guess; Victoria M Velazquez; Laura Desbourdes; Massimo Dominici; Edwin M Horwitz Journal: Blood Adv Date: 2017-12-14
Authors: X Cahu; M Labopin; S Giebel; M Aljurf; S Kyrcz-Krzemien; G Socié; M Eder; F Bonifazi; D Bunjes; S Vigouroux; M Michallet; M Stelljes; T Zuckerman; J Finke; J Passweg; I Yakoub-Agha; D Niederwieser; G Sucak; H Sengeløv; E Polge; A Nagler; J Esteve; M Mohty Journal: Bone Marrow Transplant Date: 2015-11-30 Impact factor: 5.483
Authors: Ho Cheol Shin; Yoo Jin Lee; Joon Ho Moon; Soo Jung Lee; Byung Woog Kang; Yee Soo Chae; Jong Gwang Kim; Jun Young Choi; Jong Won Seo; Yu Kyung Kim; Jang Soo Suh; Sang Kyun Sohn Journal: Korean J Intern Med Date: 2012-02-28 Impact factor: 2.884
Authors: C Greil; M Engelhardt; G Ihorst; J Duque-Afonso; K Shoumariyeh; H Bertz; R Marks; R Zeiser; J Duyster; J Finke; R Wäsch Journal: Bone Marrow Transplant Date: 2020-10-31 Impact factor: 5.483